This study is currently not recruiting participants.

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

Investigating Treatment for Advanced Solid Tumors

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.

Detailed description of study

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Solid Tumor
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the effects of an investigational medication on advanced solid tumors that cannot be removed by surgery or have spread to other parts of the body. These tumors have not responded to standard treatments, which are the usual methods used to try to control the cancer.

Participants will receive an investigational medication to see how it affects their tumors. The study will monitor the participants' health and the response of their tumors to the treatment. This involves regular check-ups and medical tests to track progress.

  • Who can participate: Participants with advanced solid tumors that cannot be removed by surgery or have spread are eligible. These tumors must not have responded to standard treatments.
  • Study details: Participants will receive an investigational medication, and their health will be monitored regularly to assess the treatment's effects on their tumors.
Updated on 19 Feb 2024. Study ID: 1601482282 (MK-3475-158)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team